News
TENX
17.72
+1.93%
0.34
Tenax Therapeutics: 'Hold' TNX-103 Data August 2026 - But With Caution Ahead
Seeking Alpha · 2d ago
LifeSci Capital Reaffirms Their Buy Rating on Tenax Therapeutics (TENX)
TipRanks · 2d ago
Weekly Report: what happened at TENX last week (0629-0703)?
Weekly Report · 2d ago
Tenax Therapeutics grants 160,000 inducement stock options to new hires
PUBT · 6d ago
Rivian Automotive, Tenax Therapeutics, Robinhood And Other Big Stocks Moving Higher On Thursday
Benzinga · 6d ago
Tenax Therapeutics Price Target Maintained With a $27.00/Share by Chardan Capital
Dow Jones · 6d ago
Tenax Therapeutics Is Maintained at Buy by Chardan Capital
Dow Jones · 6d ago
Three Years of War Changed What Governments Buy. One Player is Already Winning Contracts (NASDAQ: MDWD)
TipRanks · 6d ago
Tenax Therapeutics highlights key Phase 3 LEVEL trial
TipRanks · 6d ago
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Benzinga · 6d ago
Tenax Therapeutics expects topline Phase 3 LEVEL trial results in August 2026
PUBT · 6d ago
Tenax Therapeutics To Present Results From Phase 3 LEVEL Clinical Trial In Late-Breaking Clinical Science Session At ESC Congress 2026
Benzinga · 6d ago
Tenax Therapeutics flags announcement on LEVEL trial data presentation at ESC Congress 2026
PUBT · 6d ago
TENAX THERAPEUTICS ANNOUNCES LATE-BREAKING PRESENTATION OF LEVEL CLINICAL TRIAL DATA AT ESC CONGRESS 2026
Reuters · 6d ago
Tenax and Orion Secure Long-Term Levosimendan Supply Deal
TipRanks · 06/30 21:07
TENAX THERAPEUTICS: EXTENDS US REGULATORY APPROVAL DEADLINE TO DECEMBER 31, 2035 VIA SIXTH AMENDMENT TO ORION LICENSE - SEC FILING
Reuters · 06/30 20:37
Tenax signs oral levosimendan supply deal with Orion
PUBT · 06/30 20:32
Tenax Therapeutics Updates Executive and Employee Severance Protections
TipRanks · 06/29 20:59
Tenax Therapeutics amends executive employment agreements to expand severance, change-in-control benefits
PUBT · 06/29 20:41
Weekly Report: what happened at TENX last week (0622-0626)?
Weekly Report · 06/29 09:59
More
Webull provides a variety of real-time TENX stock news. You can receive the latest news about Tenax Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About TENX
Tenax Therapeutics, Inc. is a Phase 3 development-stage pharmaceutical company. The Company is focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The Company's products include TNX-201 (oral enteric-coated imatinib) and TNX-103 (oral levosimendan). The Company is developing dosing and a formulation of imatinib mesylate, a kinase inhibitor for the treatment of pulmonary arterial hypertension (PAH). The Company’s other programs include TNX-101 and TNX-102. Levosimendan is a calcium sensitizer/K-ATP activator developed for intravenous use in hospitalized patients with acutely decompensated heart failure. The Company has completed the Phase II trial of levosimendan in patients with PH and heart failure with preserved ejection fraction (HFpEF).